Delay of Alternative Antiviral Therapy and Poor Outcomes of Acyclovir ‐Resistant Herpes Simplex Virus Infections in Recipients of Allogeneic Stem Cell Transplant
In conclusion, acyclovir‐resistant HSV infection is more likely during the period of profound deficit in T‐cell–mediated immunity and is associated with significant morbidities. Higher doses of acyclovir prophylaxis might be needed for patients with history of HSV during pre‐engraftment or GVHD treatment. In patients who do not respond or progress after 1‐week of acyclovir therapy, testing for drug‐resistant HSV and early switch to an alternative antiviral should be considered.
This article is protected by copyright. All rights reserved.
Source: Transplant International - Category: Transplant Surgery Authors: Ella J. Ariza ‐Heredia, Roy F. Chemaly, Lokesh R. Shahani, Ying Jang, Richard Champlin, Victor E. Mulanovich Tags: Original Article Source Type: research
More News: Acyclovir | Antiviral Therapy | Cold Sores | Corticosteroid Therapy | Herpes | Microbiology | Renal Failure | Stem Cell Therapy | Stem Cells | Study | Transplants | Zovirax